Active dendritic cell immunotherapy for glioblastoma: Current status and challenges (Q38301084)

1 September 2017

1 reference

title

Active dendritic cell immunotherapy for glioblastoma: Current status and challenges (English)

1 reference

1 September 2017

1 reference

1 reference

1 reference

Mark Richardson

13

0 references

Farzin Farzaneh

object named as

Farzin Farzaneh

14

0 references

author name string

Stavros Polyzoidis

1

1 reference

1 September 2017

Juel Tuazon

2

1 reference

1 September 2017

Lucy Brazil

3

1 reference

1 September 2017

Ronald Beaney

4

1 reference

1 September 2017

Safa Taha Al-Sarraj

5

1 reference

1 September 2017

Lawrence Doey

6

1 reference

1 September 2017

Jamie Logan

7

1 reference

1 September 2017

Victoria Hurwitz

8

1 reference

1 September 2017

Jozef Jarosz

9

1 reference

1 September 2017

Ranjeev Bhangoo

10

1 reference

1 September 2017

Richard Gullan

11

1 reference

1 September 2017

Aleksandar Mijovic

12

1 reference

1 September 2017

Keyoumars Ashkan

15

1 reference

1 September 2017

publication date

26 December 2014

1 reference

British Journal of Neurosurgery

1 September 2017

published in

1 reference

1 September 2017

volume

29

1 reference

1 September 2017

issue

2

1 reference

1 September 2017

page(s)

197-205

1 reference

Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas

1 September 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2014.994473

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2014.994473

The art of gene therapy for glioma: a review of the challenging road to the bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2014.994473

Sipuleucel-T: in metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2014.994473

Cancer immunotherapy via dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2014.994473

T cells traffic from brain to cervical lymph nodes via the cribroid plate and the nasal mucosa

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2014.994473

Multifocal glioblastoma with remote cutaneous metastasis: a case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2014.994473

A fresh look at tumor immunosurveillance and immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2014.994473

Immature mesenchymal stem cell-like pericytes as mediators of immunosuppression in human malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2014.994473

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2014.994473

Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2014.994473

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2014.994473

Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2014.994473

Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2014.994473

Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2014.994473

Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2014.994473

Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2014.994473

Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2014.994473

Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2014.994473

Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2014.994473

Results of a phase I dendritic cell vaccine trial for malignant astrocytoma: potential interaction with adjuvant chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2014.994473

Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2014.994473

A phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2014.994473

Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2014.994473

Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulo

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2014.994473

Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2014.994473

Adjuvant immunotherapy with whole-cell lysate dendritic cells vaccine for glioblastoma multiforme: a phase II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2014.994473

Clinical application of a dendritic cell vaccine raised against heat-shocked glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2014.994473

Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2014.994473

α-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2014.994473

Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2014.994473

Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2014.994473

Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2014.994473

Counterbalancing risks and gains from extended resections in malignant glioma surgery: a supplemental analysis from the randomized 5-aminolevulinic acid glioma resection study. Clinical article

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2014.994473

Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2014.994473

Generation of cytotoxic immune responses during the progression of a rat glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2014.994473

Active immunotherapy for advanced intracranial murine tumors by using dendritic cell-tumor cell fusion vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2014.994473

Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2014.994473

10.3109/02688697.2014.994473

21 January 2018

Identifiers

DOI

1 reference

1 September 2017

1 reference